Atrial fibrillation is the most common and potentially difficult to treat cardiac arrhythmia encountered in clinical practice. It is classified according to its temporal pattern as paroxysmal (self-limiting), persistent (amenable to cardioversion), or permanent. 1 Although the frequency of each type depends on the population studied, it is estimated that paroxysmal fibrillation accounts for 35% to 66% of all cases of atrial fibrillation. [2] [3] [4] The prevalence of this disorder increases with age, rising above 5% in people older than 65 years of age. 5 Independent risk factors for fibrillation, from long-term follow-up data of the Framingham study, include male sex, hypertension, diabetes, heart failure, and valvular heart disease. 6 Because of its high prevalence, hypertension accounts for most cases of fibrillation in the population compared with all other risk factors. Among chronic kidney disease patients starting dialysis, 36% have heart failure, and an additional 7% develop heart failure while receiving dialysis. 7 Consequently, it is not unexpected that those patients on renal replacement therapy are at a particularly increased risk for the development of atrial fibrillation compared with the general population.
The prevalence of atrial fibrillation in dialysis patients is also driven by the changing age distribution of this population. Thirty years ago, approximately 27% of new end-stage kidney disease patients in the United States who began chronic renal replacement therapy were Ն65 years of age. In 2005, the total number of patients who started renal replacement therapy in the United States was 106,912, of which 52,434 (49%) were Ͼ65 years of age. 8 Although the incidence rates between 2000 and 2005 have been relatively stable for most age groups (changing Ͻ3.0%), the incidence rate has grown 10% from 1570 to 1725 per million for patients Ն75 years of age.
In the general population, atrial fibrillation may affect longevity because it is associated with approximately doubling all-cause and cardiovascular mortality rates. 9, 10 Mortality, as expected in this setting, is driven by cerebrovascular events, progressive ventricular dysfunction, and increased coronary mortality. In addition, age-adjusted incidence of stroke in the Framingham study after 34 years of follow-up was nearly fivefold higher when nonrheumatic atrial fibrillation was present compared with those without atrial fibrillation. 11 The mechanism that triggers most atrial premature beats that initiate frequent paroxysms of fibrillation originates in the pulmonary veins, which has generated interest in ablative therapy of this region in selected patients. 12 Despite its important clinical relevance and potential effect on morbidity and mortality, there have been very limited data studying this comorbidity in dialysis patients in the United States and only a few worldwide published reports in this population. [13] [14] [15] [16] In this issue, Winkelmayer et al. examine the epidemiology (including prevalence, risk factors, and mortality) of atrial fibrillation in patients on maintenance dialysis in the United States over a period of 15 years (1992 to 2006) using the U.S. Renal Data System annual cohorts. The overall prevalence of atrial fibrillation in this patient population exceeded 10% in 2006. In older patients, the prevalence was 13.2% in patients aged 65 to 75 years, 19.2% in those aged 75 to 85 years, and 22.5% in those Ͼ85 years of age. More importantly, atrial fibrillation was associated with considerable excess mortality in this population (crude 1-year mortality of 38.8% versus 18.6%), although the odds ratio was attenuated in the fully adjusted model. This study presents the first comprehensive evaluation of atrial fibrillation in patients on maintenance dialysis in the United States. It provides a contemporary estimate of the prevalence of fibrillation in this population with an impressive overall higher prevalence compared with the general population (8% versus 1%). The results also reflect the growing proportion of elderly individuals on maintenance dialysis. As indicated by the authors, the study is limited by its cross-sectional nature and reliance on medical claims data, which could be potentially incomplete. Another issue is the temporal trend in atrial fibrillation prevalence, in which the number of affected patients increased more than sixfold during the study period.
Can secular trends in the diagnosis and aggressive coding of atrial fibrillation favor increased detection of this arrhythmia in more recent years and can it explain this phenomenon? As the authors suggest, aggressive coding may explain the significant increase in atrial fibrillation rates in recent years (as shown in Figure 3 of Winkelmayer et al., approximately 50% increase in the adjusted relative prevalence in 2006 versus 1992). Nonetheless, these results are consistent with the temporal trend observed in the general population, in which fibrillation is also becoming more prevalent with time, even after adjustment for age and structural heart disease. 17 The difference in atrial fibrillation risk among races is also similar to what has been observed in the general population, in which prevalence of atrial fibrillation was higher in whites than in blacks in the AnTicoagulation and Risk Factors in Atrial Fibrillation study (2.2% versus 1.5%; P Ͻ 0.001). 18 Although the authors attempted to capture those with recurrent paroxysmal, persistent, or permanent atrial fibrillation, the relative prevalence of each type was not reported. It is also quite possible that paroxysmal fibrillation, particularly those triggered by dialysis treatment itself, were not accurately captured.
Determining the pattern of atrial fibrillation in dialysis has significant clinical and therapeutic implications for this particular patient population. Do dialysis patients have an increased risk for permanent atrial fibrillation, which may require chronic anticoagulation or anti-arrhythmic therapy? If further studies can define the independent effect of atrial fibrillation on morbidity and mortality in the dialysis population, it will directly inform the aggressiveness with which we ought to pursue its clinical modification, recognizing the real risk of stroke in treating these patients. 19, 20 Despite its limitations, Winklemayer's study is important and lays the groundwork for future studies designed to explore specific patterns of atrial fibrillation in this population, potential preventive measures, and treatment options such as anticoagulation. Defining the dividends realized from identification and treatment of atrial fibrillation in the dialysis population will be of enormous clinical consequence for our patients.
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